-
New Hope: FDA Expands Approval for Anktiva in Bladder Cancer Treatment
NASDAQ: $IBRX A Major Milestone in Bladder Cancer Care The landscape for treating non-muscle invasive bladder cancer (NMIBC) has just seen a significant shift. The FDA has officially expanded the approval of Anktiva (nogapendekin alfa inbakicept-pmln), providing a new, vital option for patients facing one of the most challenging forms of this disease. Understanding the…
-
A New Frontier: FDA Approves Imfinzi for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
A Significant Breakthrough in Bladder Cancer Care For patients facing non-muscle invasive bladder cancer (NMIBC), treatment options have historically been limited, particularly for those whose cancer does not respond to standard BCG therapy. Recently, the landscape of care shifted with the FDA approval of Imfinzi (durvalumab), marking a major milestone as the first and only…